Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT-PD Cohort 2
ACTRN12626001278325Phase 2Not yet recruiting
- Sponsor
- Curtin University
- Start
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of probucol in Parkinson's disease (PD), sponsored by Curtin University. Primary endpoints: Safety of probucol in advanced Parkinson's disease, Tolerability of probucol in advanced Parkinson's disease and 1 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
probucol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ACTRN12626001278325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001278325.